HMicro picks up $10M+ to advance wireless system-on-a-chip tech

DNA computer

HMicro, which makes wireless system-on-a-chip biosensor tech, raised a $10.2 million Series C round. It will use the funding to drive the development and commercialization of its biosensor platform, disposable wireless patch and mobile and fixed location receiver devices.

Fremont, CA-based HMicro was founded in 2008 to develop a silicon-based wireless sensing platform and related products for medical companies, HMicro said in a statement. Its Reach Module platform includes a chip, biosensor patches and receiver devices for use in medical devices.

HMicro is co-developing wireless, clinical-grade devices for the monitoring of physiology, according to the company. Its first focus is a single-patient ECG device. Using its wireless technology, HMicro hopes to replace the wiring harness used in ECG--electrodes attached to the chest and leads connecting them to the patient monitor--with a much smaller wireless solution. HMicro will announce relationships with various partners “in the coming months,” said CEO Surendar Magar in the statement.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

OEM Partners, which will be commercializing Reach-based products, participated in the round, along with existing investors XSeed Capital, Seraph Group and Uniquest. HMicro previously raised $5.5 million in a 2014 Series B round.

“We are excited to expand our equity partnerships to firms who will be immediately leveraging our technology into their development initiatives and customer solution roadmaps,” Magar said in the statement. “Migrating clinical healthcare to the wireless domain is a huge challenge which we believe is best met by pooling resources from committed supply and OEM partners.”


Suggested Articles

Inotrem and Roche’s diagnostics division have upgraded their years-long collaboration on a plasma test for septic shock, with a new worldwide deal.

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.